Despite partnership with Tilray (TLRY), Novartis (NVS) says marijuana isn't a priority

: TLRY | Tilray, Inc. - Class 2  News, Ratings, and Charts

TLRY – Tilray is working with Novartis’ generic drug business Sandoz.

  • Novartis CEO Vas Narasimhan says cannabis is not a priority for the Swiss drugmaker despite its partnership with Canadian marijuana giant Tilray.
  • Narasimhan says he is trying to shape Novartis into a company that is “uniquely placed” in the health-care system, balancing between consumer health needs and more rare health concerns like gene diseases.

Novartis CEO Vas Narasimhan said Tuesday that cannabis is not a priority for the Swiss drugmaker despite its partnership with Canadian marijuana giant Tilray.

Tilray is working with Novartis’ generic drug business Sandoz and supplying non-smokable and non-combustible medical cannabis products where it is legally allowed. As a part of the deal announced in December, Tilray and Sandoz may co-brand certain products as well as develop new ones. It was the first major partnership between a pharmaceutical company and a cannabis business.

But speaking with CNBC’s Jim Cramer from CNBC’s “Healthy Returns” conference in New York City, Narasimhan said cannabis is “not a focus” for the pharma company.

Narasimhan said he is instead trying to shape Novartis into a company that is “uniquely placed” in the health-care system, balancing between more common ailments such as dry-eye disease or migraines and more rare health concerns like gene diseases, which affects 350 million people worldwide.

The Swiss drugmaker is expected this year to launch its gene therapy called Zolgensma for spinal muscular atrophy, a muscle-wasting disease and leading genetic cause of infant mortality, affecting one in every 11,000 live births. The treatment is estimated to boast a price tag between $1.5 million and $5 million.

In his interview Tuesday, Narasimhan said he’s “hopeful” the company will get approval for the gene therapy soon. “We believe in the long run we can bring meaningful innovation … and this can potentially cure kids of a disease,” he added.


Tilray Inc. shares were unchanged in after-hours trading Tuesday. Year-to-date, Tilray, Inc. - Class 2 (TLRY - Get Rating) has declined -36.80%, versus a 15.14% rise in the benchmark S&P 500 index during the same period.

Tilray, Inc. - Class 2 (TLRY - Get Rating) currently has a StockNews.com POWR Rating of NR (Not Rated), and is ranked # of 202 stocks in the Medical – Pharmaceuticals category.


This article is brought to you courtesy of CNBC.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

: hexo | HEXO Corp. Common Shares News, Ratings, and Charts

Why this analyst just rated shares of HEXO a “buy”

Yesterday MKM Partners analyst Bill Kirk initiated coverage of Hexo Corp. (HEXO) with a "buy" rating.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

What is the Worst Case Scenario for Stocks?

We need to consider just how bad things would get for the S&P (SPY) if the China deal fell apart. Yes, other indices would likely take it even harder. Let's review how this would likely unfold and our trading strategies.
: CGC | Canopy Growth Corporation  News, Ratings, and Charts

What's next for Canopy Growth (CGC), as Bruce Linton finally moves on

For the world's largest cannabis company by market cap, Canopy Growth (CGC) has seen its fair share of shake-ups in the past few months.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

What Quadruple Witching Friday Means for Investors

A bigger factor in the dampening of the witching effect is the explosion of new products and expansion of expirations offered. Continue reading to see what quadruple witching Friday means for investors.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

Repo Market Chaos Could Lead to a Crisis

Chaos in short-term funding markets this week forced the Federal Reserve to step in with a series of overnight rescue operations. Continue reading for more details.

Read More Stories


More Tilray, Inc. - Class 2 (TLRY) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TLRY News
Page generated in 1.341 seconds.